His work in the fields of Organic chemistry overlaps with other areas such as Crystallography. His research combines Crystallization and Organic chemistry. His research on Radiation therapy is centered around Radiation treatment planning, Radiation oncology and Chemoradiotherapy. Research on Mammary gland, Risk factors for breast cancer and Breast tissue is a part of his Breast cancer study. Hodgkin lymphoma and Primary central nervous system lymphoma are the focus of his Lymphoma studies. A significant part of his Methotrexate research incorporates Primary central nervous system lymphoma and Antimetabolite studies. Joachim Yahalom incorporates Antimetabolite and Methotrexate in his research. Chemical engineering and Inorganic chemistry are fields of study that overlap with his Physical chemistry research. He applies his multidisciplinary studies on Chemical engineering and Metallurgy in his research.
His work on Internal medicine is being expanded to include thematically relevant topics such as Regimen. In his work, Joachim Yahalom performs multidisciplinary research in Metallurgy and Chemical engineering. Chemical engineering and Metallurgy are two areas of study in which Joachim Yahalom engages in interdisciplinary work. Joachim Yahalom combines Oncology and Surgery in his research. Joachim Yahalom performs multidisciplinary study on Surgery and Oncology in his works. In his works, Joachim Yahalom undertakes multidisciplinary study on Chemotherapy and Cyclophosphamide. In his works, he undertakes multidisciplinary study on Lymphoma and Chemotherapy. Physical chemistry and Anode are frequently intertwined in his study. Joachim Yahalom incorporates Anode and Electrode in his research.
In his study, which falls under the umbrella issue of Natural (archaeology), Stage (stratigraphy) is strongly linked to Paleontology. Joachim Yahalom connects Stage (stratigraphy) with Paleontology in his research. Joachim Yahalom regularly ties together related areas like Diffuse large B-cell lymphoma in his Internal medicine studies. He combines Radiation therapy and Mantle cell lymphoma in his studies. Borrowing concepts from Radiation therapy, he weaves in ideas under Mantle cell lymphoma. He undertakes multidisciplinary studies into Lymphoma and Follicular lymphoma in his work. He integrates several fields in his works, including Follicular lymphoma and Lymphoma. His work often combines Oncology and Cancer studies. In his papers, he integrates diverse fields, such as Cancer and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes
Daniel J. Klionsky;Hagai Abeliovich;Patrizia Agostinis;Devendra K. Agrawal.
A Novel Response of Cancer Cells to Radiation Involves Autophagy and Formation of Acidic Vesicles
Shoshana Paglin;Timothy Hollister;Thomas Delohery;Nadia Hackett.
Cancer Research (2001)
Treatment for Primary CNS Lymphoma: The Next Step
Lauren E. Abrey;Joachim Yahalom;Lisa M. DeAngelis.
Journal of Clinical Oncology (2000)
Long-term survival in primary CNS lymphoma.
Lauren E. Abrey;Lisa M. DeAngelis;Joachim Yahalom.
Journal of Clinical Oncology (1998)
Combined modality therapy for primary CNS lymphoma.
Lisa M. DeAngelis;Joachim Yahalom;Howard T. Thaler;Uma Kher.
Journal of Clinical Oncology (1992)
Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model
Lauren E. Abrey;Leah Ben-Porat;Katherine S. Panageas;Joachim Yahalom.
Journal of Clinical Oncology (2006)
Superior Vena Cava Syndrome with Malignant Causes
Lynn D. Wilson;Frank C. Detterbeck;Joachim Yahalom.
The New England Journal of Medicine (2007)
Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).
Lena Specht;Joachim Yahalom;Tim Illidge;Anne Kiil Berthelsen.
International Journal of Radiation Oncology Biology Physics (2014)
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model
Craig H. Moskowitz;Stephen D. Nimer;Andrew D. Zelenetz;Tania Trippett.
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
Tarun Kewalramani;Andrew D. Zelenetz;Stephen D. Nimer;Carol Portlock.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: